Dermatology

Latest News

Dupilumab Shows Higher 2-Year Drug Survival Than Other Targeted Therapies for Atopic Dermatitis
Dupilumab Shows Higher 2-Year Drug Survival Than Other Targeted Therapies for Atopic Dermatitis

December 15th 2025

Dupilumab shows superior 2-year drug survival rates in atopic dermatitis compared to other biologics and JAK inhibitors, highlighting its effectiveness in treatment persistence.

Two Global Phase 3 Trials Confirm Efficacy of Rocatinlimab for People With Moderate-to-Severe Atopic Dermatitis / image credit: MJH life sciences
Two Global Phase 3 Trials Confirm Efficacy of Rocatinlimab for People With Moderate-to-Severe Atopic Dermatitis

December 11th 2025

New Genetic Evidence Supports a Causal Link Between Psoriasis and Depression / image credit ©Ольга Тернавская/stock.adobe.com
Genetic Evidence Supports a Causal Link Between Psoriasis and Depression

December 10th 2025

Dupilumab and Other Monoclonals Rank Highly for Moderate-to-Severe Atopic Dermatitis, Network Meta-Analysis Shows / Image credit: ©aamylya/AdobeStock
Dupilumab and Other Monoclonals Rank Highly for Moderate-to-Severe Atopic Dermatitis, Network Meta-Analysis Shows

December 9th 2025

Early Biologic Therapy for Hidradenitis Suppurativa Supported by Majority of Specialists, Survey Shows / image credit: ©syahrir/AdobeStock
Early Biologic Therapy for Hidradenitis Suppurativa Supported by Majority of Specialists, Survey Shows

December 8th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.